These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 8098393)

  • 1. Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma.
    Presant CA; Scolaro M; Kennedy P; Blayney DW; Flanagan B; Lisak J; Presant J
    Lancet; 1993 May; 341(8855):1242-3. PubMed ID: 8098393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated mucocutaneous Kaposi's sarcoma.
    Girard PM; Bouchaud O; Goetschel A; Mukwaya G; Eestermans G; Ross M; Rozenbaum W; Saimot AG
    AIDS; 1996 Jun; 10(7):753-7. PubMed ID: 8805866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of AIDS-related pulmonary Kaposi's sarcoma with liposomal daunorubicin.
    Schürmann D; Dormann A; Grünewald T; Ruf B
    Eur Respir J; 1994 Apr; 7(4):824-5. PubMed ID: 8005268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma.
    Gill PS; Wernz J; Scadden DT; Cohen P; Mukwaya GM; von Roenn JH; Jacobs M; Kempin S; Silverberg I; Gonzales G; Rarick MU; Myers AM; Shepherd F; Sawka C; Pike MC; Ross ME
    J Clin Oncol; 1996 Aug; 14(8):2353-64. PubMed ID: 8708728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study.
    Money-Kyrle JF; Bates F; Ready J; Gazzard BG; Phillips RH; Boag FC
    Clin Oncol (R Coll Radiol); 1993; 5(6):367-71. PubMed ID: 8305357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi's sarcoma.
    Tulpule A; Yung RC; Wernz J; Espina BM; Myers A; Scadden DT; Cabriales S; Ilaw M; Boswell W; Gill PS
    J Clin Oncol; 1998 Oct; 16(10):3369-74. PubMed ID: 9779714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal doxorubicin for treatment of AIDS-related Kaposi's sarcoma.
    Simpson JK; Miller RF; Spittle MF
    Clin Oncol (R Coll Radiol); 1993; 5(6):372-4. PubMed ID: 8305358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin.
    Gill PS; Espina BM; Muggia F; Cabriales S; Tulpule A; Esplin JA; Liebman HA; Forssen E; Ross ME; Levine AM
    J Clin Oncol; 1995 Apr; 13(4):996-1003. PubMed ID: 7707129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma.
    Coukell AJ; Spencer CM
    Drugs; 1997 Mar; 53(3):520-38. PubMed ID: 9074848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomal KS drugs approved.
    GMHC Treat Issues; 1996 Apr; 10(4):8-9. PubMed ID: 11363710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal daunorubicin marketed for HIV-related Kaposi's sarcoma.
    Am J Health Syst Pharm; 1996 Jul; 53(13):1500, 1505. PubMed ID: 8809269
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma.
    Bennett CL; Golub RM; Stinson TJ; Aboulafia DM; von Roenn J; Bogner J; Goebel FD; Stewart S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Aug; 18(5):460-5. PubMed ID: 9715842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal daunorubicin: new preparation. Kaposi's sarcoma: occasional remission.
    Prescrire Int; 1998 Apr; 7(34):41-2. PubMed ID: 10183380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomal doxorubicin: new preparation. Useful in Kaposi's sarcoma.
    Prescrire Int; 1998 Jun; 7(35):69-70. PubMed ID: 10342919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma.
    Hjortsberg C; Persson U; Lidbrink E; Bennett C
    Acta Oncol; 1999; 38(8):1063-7. PubMed ID: 10665764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma.
    Harrison M; Tomlinson D; Stewart S
    J Clin Oncol; 1995 Apr; 13(4):914-20. PubMed ID: 7707119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized cross-over comparison of liposomal daunorubicin versus observation for early Kaposi's sarcoma.
    Uthayakumar S; Bower M; Money-Kyrle J; Muyshondt C; Youle M; Hannon F; Phillips R; Gazzard BG; Boag F
    AIDS; 1996 May; 10(5):515-9. PubMed ID: 8724043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal doxorubicin in AIDS-related Kaposi's sarcoma: long-term experiences.
    Wagner D; Kern WV; Kern P
    Clin Investig; 1994 Jun; 72(6):417-23. PubMed ID: 7950152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal chemotherapies.
    Smart T
    GMHC Treat Issues; 1995; 9(7/8):13. PubMed ID: 11362653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A risk and benefit assessment of treatment for AIDS-related Kaposi's sarcoma.
    Nasti G; Errante D; Santarossa S; Vaccher E; Tirelli U
    Drug Saf; 1999 May; 20(5):403-25. PubMed ID: 10348092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.